A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors | PLOS ONE
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors | PLOS ONE
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device - ScienceDirect
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device - ScienceDirect
PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. - Abstract - Europe PMC
Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment | TCRM
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
Protocol Phase 1 Template
Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study - Escuriola Ettingshausen - 2022 -
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma | Haematologica
Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial - Lentz - 2018 - Haemophilia - Wiley Online Library
PDF) Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results
Spotlight on pomalidomide: could less be more? | Leukemia
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
Rescuing clinical trials in the United States and beyond: A call for action - ScienceDirect
Fast recruiting clinical trials – a Utopian dream or logistical nightmare? | British Journal of Cancer
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Research and Practice in Thrombosis and Haemostasis
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
trial turoctocog guardian 2 suplimentary table s4 - micompaniateatro.com
Exhibit 99.1
CLINICAL STUDY PROTOCOL
trial turoctocog guardian 2 suplimentary table s4 - micompaniateatro.com
